César Alexander Ortiz Rojas

Dr. César Alexander Ortiz Rojas

Universidade de São Paulo, São Paulo, Brazil
+1
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2023 in Science Advances
Verified
Journal Article
Open access
IWIsabel Weinhäuser
Isabel Weinhäuser
DPDiego A Pereira-Martins
Diego A Pereira-Martins
LALuciana Yamamoto de Almeida
Luciana Yamamoto de Almeida
JHJacobien R. Hilberink
Jacobien R. Hilberink
DSDouglas Silveira
Douglas Silveira
JSJan Jacob Schuringa
Jan Jacob Schuringa
It is increasingly becoming clear that cancers are a symbiosis of diverse cell types and tumor clones. Combined single-cell RNA sequencing, flow cytometry, and immunohistochemistry studies of the innate immune compartment in the bone marrow of patients with acute myeloid leukemia (AML) reveal a shift toward a tumor-supportive M2-polarized macrophage landscape with an altered transcriptional program, with enhanced fatty acid oxidation and NAD + generation. Functionally, these AML-associated macrophages display decreased phagocytic activity and intra–bone marrow coinjection of M2 macrophages together with leukemic blasts strongly enhances in vivo transformation potential. A 2-day in vitro exposure to M2 macrophages results in the accumulation of CALR low leukemic blast cells, which are now protected against phagocytosis. Moreover, M2-exposed “trained” leukemic blasts display increased mitochondrial metabolism, in part mediated via mitochondrial transfer. Our study provides insight into the mechanisms by which the immune landscape contributes to aggressive leukemia development and provides alternatives for targeting strategies aimed at the tumor microenvironment.

12 September 2021 in Oral Diseases
Verified
Journal Article
Closed access
PDF file
LALuciana Yamamoto de Almeida
Luciana Yamamoto de Almeida
FMFernanda dos Santos Moreira
Fernanda dos Santos Moreira
GSGuilherme Augusto Silva dos Santos
Guilherme Augusto Silva dos Santos
FZFlorence Juana Maria Cuadra Zelaya
Florence Juana Maria Cuadra Zelaya
César Alexander Ortiz RojasCésar Alexander Ortiz Rojas
César Alexander Ortiz Rojas
EGEdgard Graner
Edgard Graner

28 September 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
LALuciana Yamamoto de Almeida
Luciana Yamamoto de Almeida
DPDiego A. Pereira-Martins
Diego A. Pereira-Martins
IWIsabel Weinhäuser
Isabel Weinhäuser
César Alexander Ortiz RojasCésar Alexander Ortiz Rojas
César Alexander Ortiz Rojas
LCLarissa A. Cândido
Larissa A. Cândido
EREduardo Rego
Eduardo Rego
In approximately 15% of patients with acute myeloid leukemia (AML), total and phosphorylated EGFR proteins have been reported to be increased compared to healthy CD34+samples. However, it is unclear if this subset of patients would benefit from EGFR signaling pharmacological inhibition. Pre-clinical studies on AML cells provided evidence on the pro-differentiation benefits of EGFR inhibitors when combined with ATRA or ATOin vitro. Despite the success of ATRA and ATO in the treatment of patients with acute promyelocytic leukemia (APL), therapy-associated resistance is observed in 5-10% of the cases, pointing to a clear need for new therapeutic strategies for those patients. In this context, the functional role of EGFR tyrosine-kinase inhibitors has never been evaluated in APL. Here, we investigated the EGFR pathway in primary samples along with functionalin vitroandin vivostudies using several APL models. We observed that total and phosphorylated EGFR (Tyr992) was expressed in 28% and 19% of blast cells from APL patients, respectively, but not in healthy CD34+samples. Interestingly, the expression of the EGF was lower in APL plasma samples than in healthy controls. The EGFR ligand AREG was detected in 29% of APL patients at diagnosis, but not in control samples.In vitro, treatment with the EGFR inhibitor gefitinib (ZD1839) reduced cell proliferation and survival of NB4 (ATRA-sensitive) and NB4-R2 (ATRA-resistant) cells. Moreover, the combination of gefitinib with ATRA and ATO promoted myeloid cell differentiation in ATRA- and ATO-resistant APL cells.In vivo, the combination of gefitinib and ATRA prolonged survival compared to gefitinib- or vehicle-treated leukemic mice in a syngeneic transplantation model, while the gain in survival did not reach statistical difference compared to treatment with ATRA alone. Our results suggest that gefitinib is a potential adjuvant agent that can mitigate ATRA and ATO resistance in APL cells. Therefore, our data indicate that repurposing FDA-approved tyrosine-kinase inhibitors could provide new perspectives into combination therapy to overcome drug resistance in APL patients.

26 December 2024 in Bioinformatics Advances
Verified
Journal Article
Open access
ENEduardo Navarrete-Bencomo
Eduardo Navarrete-Bencomo
Anthony Vladimir Campos SeguraAnthony Vladimir Campos Segura
Anthony Vladimir Campos Segura
OSOrlando Sevillano
Orlando Sevillano
AMAna Mayanga
Ana Mayanga
JBJosé Luis Buleje
José Luis Buleje
Alexis Murillo CarrascoAlexis Murillo Carrasco
Alexis Murillo Carrasco
Motivation: The Cancer Cell Line Encyclopedia (CCLE), launched in 2008, systematically organizes multi-omic and pharmacological data from over 1000 cancer cell lines with molecular dependency maps accessible through the DepMap tool. However, DepMap lacks tools for systematic comparison of mRNAs, miRNAs, proteins, and metabolites, as well as their links to drug responses and gene signatures. Extracting this data externally requires bioinformatics expertise, limiting access for wet-lab researchers. Results: We developed ShinyTHOR, a web app for intuitive access to multi-omic (transcriptomic, metabolomic, methylomic, proteomic, and miRNomic) and drug-related data. It integrates datasets from CCLE, miRTarBase, circInteractome, and the Genomics of Drug Sensitivity in Cancer. ShinyTHOR includes six modules: (1) identifying top/bottom ten cell lines by marker expression or drug IC50, (2) single-sample Gene Set Enrichment Analysis (ssGSEA), (3) multi-analyte expression evaluation, (4) miRNA-target interactions across cancer types, (5) miRNA impact on mRNA translation via protein levels, and (6) circRNA/miRNA modulation. To validate its utility, we applied ShinyTHOR to a gastric cancer prognosis study (GES7). Availability and implementation: ShinyTHOR is freely accessible for non-commercial use at https://alexismurillo.shinyapps.io/ShinyThor, with source code available at https://github.com/Murillo22/ShinyThor.

27 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
IWIsabel Weinhäuser
Isabel Weinhäuser
DPDiego A Pereira-Martins
Diego A Pereira-Martins
César Alexander Ortiz RojasCésar Alexander Ortiz Rojas
César Alexander Ortiz Rojas
DSDouglas Silveira
Douglas Silveira
LSLuíse Araújo de Albuquerque Simões
Luíse Araújo de Albuquerque Simões
EREduardo Rego
Eduardo Rego
The SLIT-ROBO axis plays an important role in normal stem-cell biology, with possible repercussions on cancer stem cell emergence. Although the Promyelocytic Leukemia (PML) protein can regulate SLIT2 expression in the central nervous system, little is known about SLIT2 in acute promyelocytic leukemia. Hence, we aimed to investigate the levels of SLIT2 in acute promyelocytic leukemia (APL) and assess its biological activity in vitro and in vivo. Our analysis indicated that blasts with SLIT2high transcript levels were associated with cell cycle arrest, while SLIT2low APL blasts displayed a more stem-cell like phenotype. In a retrospective analysis using a cohort of patients treated with all-trans retinoic acid (ATRA) and anthracyclines, high SLIT2 expression was correlated with reduced leukocyte count (p = 0.024), and independently associated with improved overall survival (hazard ratio: 0.94; 95% confidence interval: 0.92–0.97; p < 0.001). Functionally, SLIT2-knockdown in primary APL blasts and cell lines led to increased cell proliferation and resistance to arsenic trioxide induced apoptosis. Finally, in vivo transplant of Slit2-silenced primary APL blasts promoted increased leukocyte count (p = 0.001) and decreased overall survival (p = 0.002) compared with the control. In summary, our data highlight the tumor suppressive function of SLIT2 in APL and its deteriorating effects on disease progression when downregulated.

12 September 2023 in Frontiers in Genetics
Verified
Journal Article
Open access
MSMariana Belén Velásquez Sotomayor
Mariana Belén Velásquez Sotomayor
ASAnthony Vladimir Campos Segura
Anthony Vladimir Campos Segura
RMRicardo José Asurza Montalva
Ricardo José Asurza Montalva
OMObert Marín-Sánchez
Obert Marín-Sánchez
Alexis Murillo CarrascoAlexis Murillo Carrasco
Alexis Murillo Carrasco
César Alexander Ortiz RojasCésar Alexander Ortiz Rojas
César Alexander Ortiz Rojas
Gastric cancer (GC) ranks fifth in incidence and fourth in mortality worldwide. The high death rate in patients with GC requires new biomarkers for improving survival estimation. In this study, we performed a transcriptome-based analysis of five publicly available cohorts to identify genes consistently associated with prognosis in GC. Based on the ROC curve, patients were categorized into high and low-expression groups for each gene using the best cutoff point. Genes associated with survival (AUC > 0.5; univariate and multivariate Cox regressions, p < 0.05) were used to model gene expression-based scores by weighted sum using the pooled Cox β regression coefficients. Cox regression (p < 0.05), AUC > 0.5, sensitivity > 0.5, and specificity > 0.5 were considered to identify the best scores. Gene set enrichment analysis (KEGG, REACTOME, and Gene Ontology databases), as well as microenvironment composition and stromal cell signatures prediction (CIBERSORT, EPIC, xCell, MCP-counter, and quanTIseq web tools) were performed. We found 11 genes related to GC survival in the five independent cohorts. Then, we modeled scores by calculating all possible combinations between these genes. Among the 2,047 scores, we identified a panel based on the expression of seven genes. It was named GES7 and is composed of CCDC91, DYNC1I1, FAM83D, LBH, SLITRK5, WTIP, and NAP1L3 genes. GES7 features were validated in two independent external cohorts. Next, GES7 was found to recategorize patients from AJCC TNM stages into a best-fitted prognostic group. The GES7 was associated with activation of the TGF-β pathway and repression of anticancer immune cells. Finally, we compared the GES7 with 30 previous proposed scores, finding that GES7 is one of the most robust scores. As a result, the GES7 is a reliable gene-expression-based signature to improve the prognosis estimation in GC.